Misplaced Pages

Potrasertib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Boghog (talk | contribs) at 11:38, 29 December 2024 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 11:38, 29 December 2024 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Pharmaceutical compound
Potrasertib
Clinical data
Other namesIMP7068
Identifiers
IUPAC name
  • 7-(2,6-dichlorophenyl)-12-anilino]-2,5,7,11,13-pentazatricyclotrideca-1(13),5,9,11-tetraen-8-one
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H30Cl2N8O
Molar mass565.50 g·mol
3D model (JSmol)
SMILES
  • C1CN(C(N1C)C)C2=C(C=C(C=C2)NC3=NC=C4C(=N3)N5CCN=C5N(C4=O)C6=C(C=CC=C6Cl)Cl)C
InChI
  • InChI=InChI=1S/C28H30Cl2N8O/c1-16-12-19(8-9-23(16)36-14-17(2)35(4)18(3)15-36)33-27-32-13-20-25(34-27)37-11-10-31-28(37)38(26(20)39)24-21(29)6-5-7-22(24)30/h5-9,12-13,17-18H,10-11,14-15H2,1-4H3,(H,32,33,34)/t17-,18+
  • Key:BNVDJVMTLDUCGH-HDICACEKSA-N

Potrasertib is an investigational new drug that is being evaluated for the treatment of advanced solid tumors. It is oral inhibitor of WEE1 kinase, a key regulator of cell cycle checkpoints, currently being developed by IMPACT Therapeutics.

References

  1. "IMP 7068". AdisInsight. Springer Nature Switzerland AG.
  2. Wang Z, Li W, Li F, Xiao R (January 2024). "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology. 150 (1): 13. doi:10.1007/s00432-023-05527-y. PMC 10794259. PMID 38231277.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: